Janus Henderson Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Janus Henderson Group’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$139M	Sell	3,492,977 -600,631	-15%	-$15.4M	0.07%	245
2025 Q4	$102M	Sell	4,093,608 -1,314,591	-24%	-$33.3M	0.05%	283
2025 Q3	$131M	Sell	5,408,199 -1,124,569	-17%	-$20M	0.06%	232
2025 Q2	$85.8M	Buy	6,532,768 +610,282	+10%	+$7.73M	0.04%	292
2025 Q1	$86.4M	Buy	5,922,486 +1,012,999	+21%	+$16.6M	0.05%	283
2024 Q4	$82.2M	Buy	4,909,487 +3,614,623	+279%	+$59.9M	0.04%	298
2024 Q3	$20.7M	Buy	+1,294,864	New	+$15.9M	0.01%	571
2023 Q1	–	Sell	-2,114,519	Closed	-$6.58M	–	2692
2022 Q4	$6.58M	Sell	2,114,519 -3,775,393	-64%	-$14M	﹤0.01%	806
2022 Q3	$23.6M	Buy	5,889,912 +2,461,392	+72%	+$11.3M	0.01%	641
2022 Q2	$16.7M	Sell	3,428,520 -2,189,299	-39%	-$14M	0.01%	597
2022 Q1	$50.4M	Sell	5,617,819 -125,578	-2%	-$1.14M	0.02%	497
2021 Q4	$63.1M	Buy	5,743,397 +136,095	+2%	+$1.83M	0.03%	478
2021 Q3	$91.4M	Sell	5,607,302 -73,631	-1%	-$1.52M	0.04%	374
2021 Q2	$120M	Buy	+5,680,933	New	+$134M	0.05%	337

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group's CNTA Position: Q1 2026 in Review

Janus Henderson Group reduced its Centessa Pharmaceuticals (CNTA) stake by 15% in Q1 2026, selling an estimated $15.4M and leaving 3,492,977 shares worth $139M. The position accounts for 0.07% of the portfolio, ranked #245.

Janus Henderson Group first reported a position in CNTA in Q2 2021 and has held it in 14 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Janus Henderson Group held 3,492,977 shares of Centessa Pharmaceuticals worth $139M as of Q1 2026.
Janus Henderson Group sold 600,631 Centessa Pharmaceuticals shares in Q1 2026, an estimated $15.4M.
Centessa Pharmaceuticals made up 0.07% of Janus Henderson Group's portfolio in Q1 2026, its #245 holding.
Janus Henderson Group first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.